A detailed history of Hrt Financial LP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Hrt Financial LP holds 15,432 shares of BMY stock, worth $884,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,432
Holding current value
$884,716
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$39.66 - $51.75 $612,033 - $798,606
15,432 New
15,432 $798,000
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $10.7 Million - $12.8 Million
221,739 New
221,739 $11.4 Million
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $14.6 Million - $16.2 Million
229,452 New
229,452 $14.7 Million
Q4 2022

Feb 10, 2023

BUY
$68.48 - $81.09 $5.18 Million - $6.14 Million
75,662 New
75,662 $5.44 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $20.3 Million - $22.4 Million
-279,862 Reduced 90.16%
30,539 $2.35 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $19.1 Million - $22.9 Million
310,401 New
310,401 $22.7 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $18 Million - $21 Million
-303,393 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$61.91 - $67.42 $4.36 Million - $4.75 Million
70,388 Added 30.21%
303,393 $20.3 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $10.3 Million - $11.6 Million
174,274 Added 296.73%
233,005 $14.7 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $3.39 Million - $3.84 Million
58,731 New
58,731 $3.64 Million
Q3 2020

Nov 13, 2020

SELL
$57.43 - $63.64 $37.9 Million - $42 Million
-660,374 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$54.82 - $64.09 $36.2 Million - $42.3 Million
660,374 New
660,374 $38.8 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.